[8-K] Lyra Therapeutics, Inc. Reports Material Event
Lyra Therapeutics filed an 8-K reporting it announced financial results for the quarter ended June 30, 2025. The filing states the company furnished a press release as Exhibit 99.1 and posted a corporate presentation on its website, furnished as Exhibit 99.2. Both exhibits are expressly described as "furnished, and not filed," and the company disclaims any obligation to update the presentation. The filing identifies Lyra's common stock as trading under the symbol LYRA on The Nasdaq Capital Market and indicates the company is an emerging growth company. The report is signed by CFO Jason Cavalier on August 12, 2025.
Lyra Therapeutics ha presentato un modulo 8-K comunicando i risultati finanziari per il trimestre chiuso al 30 giugno 2025. Nel documento la società dichiara di aver fornito un comunicato stampa come Allegato 99.1 e di aver pubblicato una presentazione aziendale sul proprio sito web, fornita come Allegato 99.2. Entrambi gli allegati sono espressamente indicati come "forniti, non depositati" e la società declina qualsiasi obbligo di aggiornare la presentazione. Il modulo indica che le azioni ordinarie di Lyra sono quotate con il simbolo LYRA sul Nasdaq Capital Market e che la società è una società emergente in fase di crescita. Il rapporto è firmato dal CFO Jason Cavalier il 12 agosto 2025.
Lyra Therapeutics presentó un formulario 8-K notificando que anunció los resultados financieros del trimestre cerrado el 30 de junio de 2025. El documento indica que la compañía aportó un comunicado de prensa como Anexo 99.1 y publicó una presentación corporativa en su sitio web, aportada como Anexo 99.2. Ambos anexos se describen expresamente como "suministrados, y no presentados" y la empresa renuncia a cualquier obligación de actualizar la presentación. El informe identifica las acciones ordinarias de Lyra como cotizadas bajo el símbolo LYRA en The Nasdaq Capital Market e indica que la compañía es una empresa emergente en fase de crecimiento. El informe está firmado por el CFO Jason Cavalier el 12 de agosto de 2025.
Lyra Therapeutics는 2025년 6월 30일로 끝나는 분기의 재무실적을 발표했다고 보고하는 8-K를 제출했습니다. 제출 문서에는 회사가 보도자료를 증빙서류(Exhibit) 99.1로 제공했고, 회사 웹사이트에 기업 프레젠테이션을 게시해 증빙서류 99.2로 제공했다고 기재되어 있습니다. 두 증빙서류는 명시적으로 "제공된 것이며 제출된 것이 아니다(furnished, and not filed)"라고 설명되어 있고, 회사는 프레젠테이션을 업데이트할 의무가 없음을 부인합니다. 문서는 Lyra의 보통주가 Nasdaq Capital Market에서 LYRA라는 심볼로 거래되고 있음을 밝히고, 회사가 성장 중인 신흥 기업임을 표시합니다. 보고서는 재무책임자(CFO) Jason Cavalier가 2025년 8월 12일에 서명했습니다.
Lyra Therapeutics a déposé un formulaire 8-K indiquant qu'elle avait annoncé ses résultats financiers pour le trimestre clos le 30 juin 2025. Le dépôt précise que la société a fourni un communiqué de presse en tant que Pièce 99.1 et a mis en ligne une présentation d'entreprise, fournie comme Pièce 99.2. Les deux pièces sont expressément qualifiées de "fournies, et non déposées" et la société décline toute obligation de mettre à jour la présentation. Le rapport indique que les actions ordinaires de Lyra se négocient sous le symbole LYRA sur le Nasdaq Capital Market et précise que la société est une entreprise émergente en croissance. Le rapport est signé par le directeur financier Jason Cavalier le 12 août 2025.
Lyra Therapeutics hat ein Formular 8-K eingereicht und mitgeteilt, dass es seine Finanzergebnisse für das zum 30. Juni 2025 endende Quartal veröffentlicht hat. In der Einreichung heißt es, dass das Unternehmen eine Pressemitteilung als Anlage 99.1 zur Verfügung gestellt und eine Unternehmenspräsentation auf seiner Website veröffentlicht hat, ebenfalls als Anlage 99.2 bereitgestellt. Beide Anlagen werden ausdrücklich als "bereitgestellt und nicht eingereicht" bezeichnet, und das Unternehmen lehnt jede Verpflichtung zur Aktualisierung der Präsentation ab. Die Einreichung nennt die Stammaktien von Lyra, die unter dem Symbol LYRA am Nasdaq Capital Market gehandelt werden, und weist darauf hin, dass das Unternehmen ein aufstrebendes Wachstumsunternehmen ist. Der Bericht ist vom CFO Jason Cavalier am 12. August 2025 unterschrieben.
- Quarterly results announced for the period ended June 30, 2025, with a press release furnished as Exhibit 99.1
- Investor presentation posted on the company's website and furnished as Exhibit 99.2, increasing accessibility to investor materials
- Disclosure compliance: filing executed and signed by the CFO, meeting SEC procedural requirements
- No financial figures or tables are included in the 8-K text; investors must consult the furnished exhibits for numeric results
- Exhibits furnished, not filed, meaning they are not subject to Section 18 liability and are not incorporated by reference into other filings by this document
- Company disclaims any obligation to update the presentation, limiting follow-up clarifications within this filing
Insights
TL;DR: Routine earnings disclosure and investor materials furnished; no financial figures included in this 8-K.
The filing confirms Lyra released its quarterly results for the period ended June 30, 2025 via a press release (Exhibit 99.1) and provided an investor presentation (Exhibit 99.2). Both exhibits are furnished rather than filed, meaning the 8-K itself does not include audited financial statements or the detailed numbers investors would need to assess performance. For analysts, the next step is to review the referenced exhibits on the company website or in furnished exhibit filings to extract revenue, EPS, cash position, and guidance, none of which are present in this document.
TL;DR: Disclosure practices follow standard SEC procedure; exhibits furnished to satisfy timely disclosure obligations.
The company used Item 2.02 to announce results and Item 7.01 to post an investor presentation, explicitly identifying the materials as furnished and not subject to Section 18 liabilities. The filing also states the company will not update Exhibit 99.2, which is a common disclaimer. The filing is signed by the CFO, fulfilling signature requirements. These actions reflect routine, compliant disclosure rather than a material corporate action.
Lyra Therapeutics ha presentato un modulo 8-K comunicando i risultati finanziari per il trimestre chiuso al 30 giugno 2025. Nel documento la società dichiara di aver fornito un comunicato stampa come Allegato 99.1 e di aver pubblicato una presentazione aziendale sul proprio sito web, fornita come Allegato 99.2. Entrambi gli allegati sono espressamente indicati come "forniti, non depositati" e la società declina qualsiasi obbligo di aggiornare la presentazione. Il modulo indica che le azioni ordinarie di Lyra sono quotate con il simbolo LYRA sul Nasdaq Capital Market e che la società è una società emergente in fase di crescita. Il rapporto è firmato dal CFO Jason Cavalier il 12 agosto 2025.
Lyra Therapeutics presentó un formulario 8-K notificando que anunció los resultados financieros del trimestre cerrado el 30 de junio de 2025. El documento indica que la compañía aportó un comunicado de prensa como Anexo 99.1 y publicó una presentación corporativa en su sitio web, aportada como Anexo 99.2. Ambos anexos se describen expresamente como "suministrados, y no presentados" y la empresa renuncia a cualquier obligación de actualizar la presentación. El informe identifica las acciones ordinarias de Lyra como cotizadas bajo el símbolo LYRA en The Nasdaq Capital Market e indica que la compañía es una empresa emergente en fase de crecimiento. El informe está firmado por el CFO Jason Cavalier el 12 de agosto de 2025.
Lyra Therapeutics는 2025년 6월 30일로 끝나는 분기의 재무실적을 발표했다고 보고하는 8-K를 제출했습니다. 제출 문서에는 회사가 보도자료를 증빙서류(Exhibit) 99.1로 제공했고, 회사 웹사이트에 기업 프레젠테이션을 게시해 증빙서류 99.2로 제공했다고 기재되어 있습니다. 두 증빙서류는 명시적으로 "제공된 것이며 제출된 것이 아니다(furnished, and not filed)"라고 설명되어 있고, 회사는 프레젠테이션을 업데이트할 의무가 없음을 부인합니다. 문서는 Lyra의 보통주가 Nasdaq Capital Market에서 LYRA라는 심볼로 거래되고 있음을 밝히고, 회사가 성장 중인 신흥 기업임을 표시합니다. 보고서는 재무책임자(CFO) Jason Cavalier가 2025년 8월 12일에 서명했습니다.
Lyra Therapeutics a déposé un formulaire 8-K indiquant qu'elle avait annoncé ses résultats financiers pour le trimestre clos le 30 juin 2025. Le dépôt précise que la société a fourni un communiqué de presse en tant que Pièce 99.1 et a mis en ligne une présentation d'entreprise, fournie comme Pièce 99.2. Les deux pièces sont expressément qualifiées de "fournies, et non déposées" et la société décline toute obligation de mettre à jour la présentation. Le rapport indique que les actions ordinaires de Lyra se négocient sous le symbole LYRA sur le Nasdaq Capital Market et précise que la société est une entreprise émergente en croissance. Le rapport est signé par le directeur financier Jason Cavalier le 12 août 2025.
Lyra Therapeutics hat ein Formular 8-K eingereicht und mitgeteilt, dass es seine Finanzergebnisse für das zum 30. Juni 2025 endende Quartal veröffentlicht hat. In der Einreichung heißt es, dass das Unternehmen eine Pressemitteilung als Anlage 99.1 zur Verfügung gestellt und eine Unternehmenspräsentation auf seiner Website veröffentlicht hat, ebenfalls als Anlage 99.2 bereitgestellt. Beide Anlagen werden ausdrücklich als "bereitgestellt und nicht eingereicht" bezeichnet, und das Unternehmen lehnt jede Verpflichtung zur Aktualisierung der Präsentation ab. Die Einreichung nennt die Stammaktien von Lyra, die unter dem Symbol LYRA am Nasdaq Capital Market gehandelt werden, und weist darauf hin, dass das Unternehmen ein aufstrebendes Wachstumsunternehmen ist. Der Bericht ist vom CFO Jason Cavalier am 12. August 2025 unterschrieben.
FAQ
What did Lyra Therapeutics (LYRA) disclose in the 8-K filed August 12, 2025?
Are the press release and presentation in the 8-K considered filed with the SEC?
Where can investors find the corporate presentation mentioned in the 8-K?
Does the 8-K include the financial numbers from the quarter?
Who signed the 8-K for Lyra Therapeutics?
